Physician profile
Stephen Andrew Moses
NPI 1124055876
$10,434.26
in general payments reported to CMS, 2019-2025
57 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,337 · 2020: $1,654 · 2021: $1,584 · 2022: $1,308 · 2023: $1,509 · 2024: $1,385 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,518 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,518.40 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,406.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,072.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $857.41 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $825.05 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $812.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $780.41 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $547.91 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $435.18 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.41 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $324.63 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $307.21 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $229.16 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $200.11 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Astellas Pharma US INC | $195.34 | 2019-2022 | |
| Allergan, INC. | $179.84 | 2019-2020 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.